---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-002715"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T13:26:19.768669+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Avalo regains Nasdaq minimum bid compliance; subject to 1-year panel monitor

## Summary
- Received Nasdaq letter January 30, 2024 confirming compliance with $1.00 bid price rule.
- Reverse stock split on December 28, 2023 brought stock above $1.00 since December 29, 2023.
- Mandatory panel monitor for one year from January 30, 2024; no cure period if noncompliant again.
- If noncompliant during monitor, Nasdaq will issue delist letter; company can request hearing.
- Failure to satisfy panel could result in delisting from Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001628280-24-002715
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024002715/0001628280-24-002715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024002715/avtx-20240130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-002715
- JSON: https://secwatch.observer/filing/0001628280-24-002715.json
- Plain text: https://secwatch.observer/filing/0001628280-24-002715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.